Related Experiment Video
Updated: Jul 3, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Atypical pharmacologies at beta-adrenoceptors
1Monash Institute for Pharmaceutical Sciences and Department of Pharmacology, Monash University, Clayton, Victoria, Australia. roger.summers@med.monash.edu.au
British Journal of Pharmacology
|July 22, 2008
Summary
New research reveals atypical agonist interactions at beta-adrenoceptors, suggesting novel mechanisms beyond standard signaling. These findings in beta-adrenoceptor pharmacology may influence future drug development for G-protein-coupled receptors.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- Beta-adrenoceptors (β-ARs) are key G-protein-coupled receptors (GPCRs) extensively studied.
- Previous research identified atypical antagonist actions at β1-, β2-, and β3-adrenoceptors involving biased signaling and allosteric modulation.
- Understanding GPCR ligand interactions is crucial for drug discovery.
Purpose of the Study:
- To investigate atypical agonist interactions at beta-adrenoceptors.
- To explore novel mechanisms of ligand-receptor engagement beyond classical pharmacology.
- To assess the implications of these atypical interactions for future drug development.
Main Methods:
- Analysis of ligand-directed signaling pathways.
- Investigation of potential allosteric interactions at beta-adrenoceptors.
- Assessment of physiological responses, including glucose uptake and palmitate oxidation.
Main Results:
- Some responses to BRL37344 and clenbuterol align with known beta(2)-adrenoceptor activity.
- Specific effects of BRL37344 at picomolar concentrations suggest interactions with additional, possibly allosteric, sites.
- Demonstration of atypical agonist pharmacology at beta-adrenoceptors.
Conclusions:
- Atypical agonist interactions at beta-adrenoceptors present novel mechanisms for GPCR modulation.
- These findings expand our understanding of ligand-receptor dynamics.
- The identified mechanisms have significant implications for the development of novel therapeutics targeting GPCRs.
Related Concept Videos
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...